Doer Biologics Received tens of millions RMB in its first financing
In January 2019, Doer Biologics has closed tens of millions RMB in its first financing. The Series A round was led by Kaitai Capital, with participation from Hangzhou Bairui Investment Company. Doer Biologics devotes to the development of multi-domain innovative biopharmaceutics, focusing on unmet clinical needs. Based on its MultipleBody® and XLong® long acting technology platforms, Doer biologics has developed DR10619, DR30121 and other products, which are significantly competitive in the field of NASH and AMD. Its first financing will certainly facilitate the progress of its products to IND application.
About Kaitai Captal Co. Ltd
KAITAI CAPITAL, founded in 2009, is a professional investment management organization mainly engaged in venture capital, private equity, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc. Currently, the asset under management of KAITAI CAPITAL has reached 50 billion RMB (USD$7.2B).
About Zhejiang Doer Biologics Co. Ltd
Doer Biologics, Located in Hangzhou Economic and Technological Development Zone, is a research-based biopharmaceutical company with registered capital of 30 million RMB. Focusing on the discovery of protein drugs for metabolic diseases and cancers, Doer Biologics is recognized as a Hi-Tech enterprise by Hangzhou government and supported by "QINGLAN Projects" of Hangzhou city.